NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
- Conditions
- Malignant Solid NeoplasmAdrenal Gland PheochromocytomaHematopoietic and Lymphatic System NeoplasmParaganglioma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed Tomography
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT05142241
- Locations
- 🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Conditions
- Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell CarcinomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell CarcinomaLocally Recurrent Laryngeal Squamous Cell CarcinomaLocally Recurrent Oral Cavity Squamous Cell Carcinoma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2021-11-29
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 150
- Registration Number
- NCT05136196
- Locations
- 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Rocky Mountain Regional VA Medical Center, Aurora, Colorado, United States
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
- Conditions
- Cigarette Smoking-Related Carcinoma
- Interventions
- Procedure: Biospecimen CollectionDietary Supplement: Broccoli Sprout/Broccoli Seed Extract SupplementDrug: Placebo AdministrationOther: Questionnaire Administration
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 120
- Registration Number
- NCT05121051
- Locations
- 🇺🇸
University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona, United States
🇺🇸George Washington University Medical Center, Washington, District of Columbia, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Conditions
- Endometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Mucinous AdenocarcinomaEndometrial Undifferentiated CarcinomaEndometrioid AdenocarcinomaRecurrent Endometrial Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 90
- Registration Number
- NCT05112601
- Locations
- 🇺🇸
IU Health North Hospital, Carmel, Indiana, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Augusta University Medical Center, Augusta, Georgia, United States
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
- Conditions
- Refractory Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmAdvanced Malignant Solid NeoplasmTriple-Negative Breast CarcinomaUnresectable Malignant Solid Neoplasm
- Interventions
- Drug: BET Bromodomain Inhibitor ZEN-3694Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT05111561
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Texas Medical Branch, Galveston, Texas, United States
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- Conditions
- Head and Neck Mucosal MelanomaMucosal MelanomaNasopharyngeal Mucosal MelanomaOral Cavity Mucosal MelanomaPenile Mucosal MelanomaRectal MelanomaRecurrent Mucosal MelanomaSinonasal Mucosal MelanomaUrethral MelanomaUrinary System Mucosal Melanoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Magnetic Resonance ImagingDrug: Placebo AdministrationProcedure: Positron Emission Tomography
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 99
- Registration Number
- NCT05111574
- Locations
- 🇺🇸
Sutter Auburn Faith Hospital, Auburn, California, United States
🇺🇸Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
🇺🇸Palo Alto Medical Foundation-Fremont, Fremont, California, United States
PT-112 in Subjects With Thymoma and Thymic Carcinoma
- Conditions
- Thymic Epithelial TumorRecurrent ThymomaThymic Cancer
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT05104736
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Conditions
- Anaplastic AstrocytomaDiffuse Midline Glioma, H3 K27M-MutantDiffuse Intrinsic Pontine GliomaAnaplastic Astrocytoma, Not Otherwise SpecifiedGlioblastoma, Not Otherwise SpecifiedMalignant GliomaGlioblastoma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Magnetic Resonance ImagingRadiation: Radiation Therapy
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 210
- Registration Number
- NCT05099003
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Banner Children's at Desert, Mesa, Arizona, United States
🇺🇸Phoenix Childrens Hospital, Phoenix, Arizona, United States
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
- Conditions
- Metastatic Bladder Urothelial CarcinomaAdvanced Renal Pelvis Urothelial CarcinomaAdvanced Ureter Urothelial CarcinomaStage III Urethral Cancer AJCC v8Metastatic Renal Pelvis Urothelial CarcinomaStage IV Renal Pelvis and Ureter Cancer AJCC v8Stage IV Renal Pelvis Cancer AJCC v8Stage IV Ureter Cancer AJCC v8Stage IV Urethral Cancer AJCC v8Advanced Bladder Urothelial Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 654
- Registration Number
- NCT05092958
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Cleveland Clinic-Weston, Weston, Florida, United States
🇺🇸Rush - Copley Medical Center, Aurora, Illinois, United States
Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
- Conditions
- Colorectal CarcinomaLynch Syndrome
- Interventions
- Biological: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSPProcedure: Biospecimen CollectionProcedure: Endoscopic BiopsyOther: Questionnaire Administration
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT05078866
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States